Dr. Reddy’s Q2 Delivers Solid Growth on Branded Markets and Nicotine Portfolio Strength

Dr. Reddy’s Laboratories Ltd. reported consolidated revenue of ₹88.28 billion for Q2 FY25, slightly above estimates, driven by strong performance in branded markets and its nicotine replacement therapy portfolio. Net profit stood at ₹13.47 billion, marginally below expectations. The company remains optimistic about sustained growth across therapeutic categories.

Show more

Stay Ahead – Explore Now! Bajaj Finance in Focus: Jefferies, Nomura, HSBC See Growth, Morgan Stanley Remains Overweight